SCHEMBL13929

SCHEMBL13929

NCCCCCN1CCN(c2c[nH]c(NC(=O)Nc3cc(F)c(F)cc3F)nc2=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.41
DRD2 P14416 4/20 0.34
DRD3 P35462 3/20 0.34
HTR1A P08908 3/20 0.34
HTR2A P28223 2/20 0.34
HTR2C P28335 1/20 0.34
MAPK1 P28482 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
AKT1 P31749 1/20 0.34
ADRA1A P35348 1/20 0.34
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
FPR3 P25089 1/20 0.33
FPR2 P25090 1/20 0.33
ADRA1B P35368 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13964 0.99 BACE1 (0.39) BACE1DRD2DRD3HTR1AHTR2A
SCHEMBL17354246 0.93 BACE1 (0.39) BACE1DRD2DRD3HTR1AHTR2A
SCHEMBL17354251 0.92 BACE1 (0.37) BACE1DRD2DRD3HTR1AHTR2A
SCHEMBL13638 0.89 DRD2 (0.40) BACE1DRD2DRD3HTR1AHTR2A
SCHEMBL14011 0.88 DRD2 (0.40) DRD2DRD3HTR1AHTR2AHTR2C
SCHEMBL17354291 0.85 BACE1 (0.39) BACE1DRD2DRD3HTR1AHTR2A
SCHEMBL13791 0.85 TP53 (0.40) BACE1DRD2DRD3HTR1AHTR2A
SCHEMBL13920 0.84 SLC6A4 (0.43) DRD2HTR1AHTR2AHTR1DHTR1B
SCHEMBL17354259 0.84 KMT2A (0.46) BACE1DRD2DRD3ADRA1ALMNA
SCHEMBL17354326 0.84 HTR1A (0.39) BACE1DRD2DRD3HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
WO-2011047323-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT BACE1 3238/4885DRD2 2468/4885DRD3 1527/4885
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT BACE1 3238/4885DRD2 2468/4885DRD3 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.